Dyclonine is an topical anesthetic used prior to examination to suppress the gag reflex or for pain relief from canker sores and fever blisters.
- Brand Names
- Dyclopro, Sucrets
- Generic Name
- DrugBank Accession Number
Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.
- Small Molecule
- Average: 289.4125
- Chemical Formula
- 2-(1-piperidyl)ethyl p-butoxyphenyl ketone
Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Associated Conditions
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Dyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.
- Mechanism of action
Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Target Actions Organism ASodium channel protein type 10 subunit alphainhibitor Humans
Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.
- Volume of distribution
- Protein binding
- Not Available
- Route of elimination
Approximately 30 to 60 minutes.
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
Symptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction 1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Dyclonine is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of adverse effects can be increased when Dyclonine is combined with Acetazolamide. Acetophenazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Acetophenazine. Aclidinium Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine. Alfentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfentanil. Alimemazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Alimemazine. Almotriptan The risk or severity of adverse effects can be increased when Dyclonine is combined with Almotriptan. Alosetron The risk or severity of adverse effects can be increased when Dyclonine is combined with Alosetron. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more
- Food Interactions
- Take separate from meals. Using Dyclonine in the mouth or for relief of ulcers in the stomach may cause numbness of the mouth, which increases the risk of biting injury. Avoid ingesting food for 60 minutes after use, or until the numbness has subsided.
- Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
- Product Ingredients
Ingredient UNII CAS InChI Key Dyclonine hydrochloride ZEC193879Q 536-43-6 KNZADIMHVBBPOA-UHFFFAOYSA-N
- International/Other Brands
- Dyclone (AstraZeneca)
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DycloPro Solution 10 mg/1mL Topical Septodont Inc 2019-09-01 Not applicable DycloPro Solution 5 mg/1mL Topical Septodont Inc 2019-09-01 Not applicable
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cepacol Sore Throat Spray Spray 0.1 % w/w Oral Reckitt Benckiser 1999-07-01 2012-03-23 PerioRinse Rinse 0.1 g/100mL Dental; Oral; Topical; Transmucosal CENTURA PHARMACEUTICALS INC 2016-06-16 2018-07-31 Sore Throat Relief Lozenge 3 mg / loz Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. Not applicable Not applicable Sucrets Black Cherry Lozenge 3 mg/1 Oral Insight Pharmaceuticals 2009-06-18 2017-08-31 Sucrets Childrens Cherry Lozenge 1.2 mg/1 Oral Insight Pharmaceuticals 2009-07-28 2017-08-31 Sucrets Extra Strength Mint Flav.loz 3mg Lozenge 3 mg / loz Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1994-12-31 1998-08-25 Sucrets for Kids Lozenge 1.2 mg / loz Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1992-12-31 1998-08-25 Sucrets for Kids Lozenge 1.2 mg Oral Insight Pharmaceuticals LLC 1997-08-15 Not applicable Sucrets MS Wintergreen Lozenge 3 mg/1 Oral Insight Pharmaceuticals 2009-07-28 2017-08-31 Sucrets Regular Strength Lemon Flav.loz 2mg Lozenge 2 mg / loz Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1994-12-31 1998-08-25
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Ambix First Aid Dyclonine hydrochloride (0.005 g/1g) + Phenol (0.005 g/1g) Cream Topical Organics Corporation Of America Dba Ambix Laboratories 2013-08-22 Not applicable Ambix First Aid Dyclonine hydrochloride (0.005 g/1g) + Phenol (0.005 g/1g) Cream Topical Suite K Value Added Services LLC 2013-08-19 2013-08-20 Benzethonium Chloride and Dyclonine Hydrochloride Dyclonine hydrochloride (0.75 mg/30mL) + Benzethonium chloride (0.2 mg/30mL) Liquid Topical Rite Aid Corporation 2020-02-01 Not applicable Benzethonium Chloride and Dyclonine Hydrochloride Dyclonine hydrochloride (0.75 mg/10mL) + Benzethonium chloride (0.2 mg/10mL) Liquid Topical CVS PHARMACY 2019-06-01 Not applicable Benzethonium chloride and Dyclonine hydrochloride Dyclonine hydrochloride (0.23 mg/29.6mL) + Benzethonium chloride (0.06 mg/29.6mL) Liquid Topical Walgreen Company 2012-01-12 Not applicable Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (0.75 mg/9mL) + Benzethonium chloride (0.2 mg/9mL) Liquid Topical Topco Associates LLC 2014-07-10 Not applicable Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (0.75 mg/10mL) + Benzethonium chloride (0.2 mg/10mL) Liquid Topical TARGET Corporation 2017-12-01 Not applicable Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (0.75 mg/9mL) + Benzethonium chloride (0.2 mg/9mL) Liquid Topical Kroger Co. 2017-12-06 Not applicable Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (0.75 mg/9mL) + Benzethonium chloride (0.2 mg/9mL) Liquid Topical Harris Teeter, LLC 2014-07-10 Not applicable Benzethonium chloride Plus Dyclonine hydrochloride Dyclonine hydrochloride (0.75 mg/9mL) + Benzethonium chloride (0.2 mg/9mL) Liquid Topical Chain Drug Marketing Association 2017-12-19 Not applicable
- ATC Codes
- N01BX02 — DyclonineR02AD04 — Dyclonine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Organic compounds
- Super Class
- Organic oxygen compounds
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Piperidines / Beta-amino ketones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives show 2 more
- Alkyl aryl ether / Alkyl-phenylketone / Amine / Aromatic heteromonocyclic compound / Aryl alkyl ketone / Azacycle / Benzenoid / Benzoyl / Beta-aminoketone / Ether / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organoheterocyclic compound / Organonitrogen compound / Organopnictogen compound / Phenol ether / Phenoxy compound / Piperidine / Tertiary aliphatic amine / Tertiary amine show 12 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidines, aromatic ketone (CHEBI:4724)
- Affected organisms
- Humans and other mammals
- CAS number
- InChI Key
- IUPAC Name
- Synthesis Reference
Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, "Oral Preparation of Dyclonine Hydrochloride." U.S. Patent US20080200506, issued August 21, 2008.US20080200506
- General References
- Not Available
- Download (73.4 KB)
- Astrazeneca lp
- Long Wing International Inc.
- Dosage Forms
Form Route Strength Cream Topical Liquid Oral Spray Oral 0.1 % w/w Solution Topical 10 mg/1mL Solution Topical 5 mg/1mL Rinse Dental; Oral; Topical; Transmucosal 0.1 g/100mL Patch Topical Liquid Topical Lozenge Oral 3 mg/1 Lozenge Oral 1.2 mg/1 Lozenge Oral Lozenge Oral 3 mg / loz Lozenge Oral 1.2 mg Lozenge Oral 1.2 mg / loz Lozenge Oral 2 mg / loz Lozenge Oral 2 mg Lozenge Oral 3 mg Aerosol Oral .1 % Lozenge Oral 2 mg/1 Gel Topical
Unit description Cost Unit Dyclonine hcl powder 4.9USD gDrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
- Not Available
- Experimental Properties
Property Value Source melting point (°C) 174-175 Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc. water solubility Soluble (HCl salt) Not Available logP 3.7 Not Available
- Predicted Properties
Property Value Source Water Solubility 0.046 mg/mL ALOGPS logP 4.11 ALOGPS logP 3.68 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 15.88 ChemAxon pKa (Strongest Basic) 8.36 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 29.54 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 87.07 m3·mol-1 ChemAxon Polarizability 35.14 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon
- Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9856 Caco-2 permeable + 0.7155 P-glycoprotein substrate Substrate 0.7596 P-glycoprotein inhibitor I Inhibitor 0.8077 P-glycoprotein inhibitor II Non-inhibitor 0.6392 Renal organic cation transporter Inhibitor 0.7801 CYP450 2C9 substrate Non-substrate 0.8107 CYP450 2D6 substrate Non-substrate 0.5142 CYP450 3A4 substrate Substrate 0.5313 CYP450 1A2 substrate Inhibitor 0.8914 CYP450 2C9 inhibitor Inhibitor 0.793 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.8574 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5388 Ames test Non AMES toxic 0.7961 Carcinogenicity Non-carcinogens 0.8823 Biodegradation Not ready biodegradable 0.7106 Rat acute toxicity 2.3661 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.8071 hERG inhibition (predictor II) Inhibitor 0.6351
- Mass Spec (NIST)
- Not Available
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
- Pharmacological action
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
- Gene Name
- Uniprot ID
- Uniprot Name
- Sodium channel protein type 10 subunit alpha
- Molecular Weight
- 220623.605 Da
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [Article]
- Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [Article]
Drug created on June 13, 2005 13:24 / Updated on July 23, 2021 16:03